Zoetis has announced that all UK veterinary wholesalers have been supplied with stocks of the new chewable form of Apoquel (oclacitinib).

Apoquel chewable tablets were approved by the Veterinary Medicines Directorate (VMD) in November 2021.

Apoquel Chewable contains the same active ingredient, at the same dosing regime, for the same indications as original Apoquel, but in a palatable formulation which, in a field-study of client-owned dogs, was found to have a 91.6% acceptance rate.

Dr Carly Mason, President of the British Veterinary Dermatology Study Group (BVDSG), said: “The new chewable form of Apoquel provides owners with a means of controlling itch using a tablet that can be given like a treat or mixed with a meal, making it much easier for owners and more acceptable to their pet.

“In many cases, the chewable formulation will be the obvious first-line Apoquel for veterinarians to prescribe to control canine itching while the underlying cause of allergic dermatitis is investigated.”


  1. Visser M. et al. Acceptance of oclacitinib maleate (Apoquel®) chewable tablets in client-owned dogs with allergic and atopic dermatitis. BMC Vet. Res. 2022;18:103.

PS: Whilst you're here, take a moment to see our latest job opportunities for vets.